Exploring metabolic diseases

With obesity medicines now household names, the race is on amongst the pioneers and competitor companies to bring improved products to market.

MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions, which affect around half of the adult population worldwide.

UK-based DefiniGEN has developed iPSC-derived cell lines that can replace primary human hepatocytes for toxicity testing and accelerate the development of novel liver-targeted therapeutics.